青森　達 (アオモリ　トオル)

Aomori, Tohru

写真a

所属（所属キャンパス）

薬学部 薬学科 病院薬学講座 （芝共立）

職名

准教授
このページの先頭へ▲
 

著書 【 表示 ／ 非表示 】

  • 「アンサングシンデレラ」・「治療薬マニュアル」コラボ小冊子

    青森達, 医学書院, 2020年

  • 老年医学（上）-基礎・臨床研究の最新動向-

    青森達, 望月眞弓, 日本臨牀社, 2018年

    担当ページ： 347-353

  • 早期臨床体験テキスト

    青森 達中村智徳, ネオメディカル, 2017年

  • 精神科領域におけるEBP. Progressive Pharmacist

    青森 達, 2010年

  • 薬剤師による処方支援　ワルファリン投与における処方支援

    青森 達, 医薬ジャーナル, 2008年

全件表示 >>

このページの先頭へ▲

論文 【 表示 ／ 非表示 】

  • Effect of renin-angiotensin system inhibitors on pemetrexed plus platinum-induced hematological toxicities: A multicenter retrospective study using three propensity score analyses

    Arami T., Kawazoe H., Uozumi R., Hashimoto H., Egami S., Sakiyama N., Ohe Y., Nakada H., Aomori T., Ikemura S., Yasuda H., Kawada I., Fukunaga K., Soejima K., Yamaguchi M., Nakamura T.

    Pharmazie （Pharmazie)  76 （ 6 ） 266 - 271 2021年06月

    ISSN  00317144

    　概要を見る

    Hematological toxicities induced by pemetrexed plus platinum therapy remain a critical issue in clinical practice. We hypothesized that inhibition of the renin-angiotensin system (RAS) can ameliorate pemetrexed-induced hematological toxicities through drug-drug interactions involving organic anion transporters. Thus, this study aimed to clarify whether RAS inhibitors (RASIs) could prevent pemetrexed plus platinum-induced hematological toxicities. We retrospectively analyzed data from 305 consecutive patients with non-small cell lung cancer or malignant pleural mesothelioma who received their first cycle of a pemetrexed plus platinum regimen and were treated with or without RASIs. The primary endpoint was the incidence of severe myelosuppression after the first cycle. Propensity score (PS)-matched, PS-adjusted, and inverse probability of treatment weighting (IPTW) analyses were used. The number of patients with grade ≥3 hematological toxicities was 27 (8.9%). PS-matched analyses revealed that the concomitant use of RASIs was slightly associated with a lower risk of grade ≥3 hematological toxicities (odds ratio [OR], 0.68; 95% confidence interval [CI], 0.20-2.32; p = 0.536). Additionally, sensitivity analyses using PS-adjusted and IPTW methods demonstrated similar results (OR, 0.63; 95% CI, 0.19-2.15; p = 0.463 and OR, 0.37; 95% CI, 0.11-1.29; p = 0.117, respectively). These findings suggest that RASIs might prevent pemetrexed plus platinum-induced hematological toxicities.

  • Absolute Lymphocyte Count Predicts Immune-Related Adverse Events in Patients With Non-Small-Cell Lung Cancer Treated With Nivolumab Monotherapy: A Multicenter Retrospective Study

    Egami S., Kawazoe H., Hashimoto H., Uozumi R., Arami T., Sakiyama N., Ohe Y., Nakada H., Aomori T., Ikemura S., Fukunaga K., Yamaguchi M., Nakamura T.

    Frontiers in Oncology （Frontiers in Oncology)  11 2021年05月

    研究論文（学術雑誌）, 共著, 査読有り

    　概要を見る

    Background: Among patients with advanced non-small-cell lung cancer who were treated with nivolumab monotherapy, the association of peripheral blood count data (at baseline and 2 weeks after treatment initiation) with the early onset of immune-related adverse events (irAEs) and treatment efficacy has not been clearly established. This study aimed to identify peripheral blood count data that may be predictive of the development of nivolumab-induced irAEs in a real-world clinical setting. Materials and Methods: This multicenter observational study retrospectively evaluated consecutive patients with advanced non-small-cell lung cancer undergoing nivolumab monotherapy in the second- or later-line setting between December 2015 and November 2018 at the National Cancer Center Hospital and Keio University Hospital in Japan. The primary endpoint was the association between peripheral blood count data and irAEs during the 6-week study period. Receiver operating characteristic curve and multivariable logistic regression analyses were performed. Results: Of the 171 patients evaluated, 73 (42.7%) had ≥1 irAE during the first 6 weeks following treatment initiation. The median time to irAEs from the initiation of nivolumab was 15 (interquartile range: 13–28) days. Receiver operating characteristic curve analyses revealed that the optimal cut-off values of the absolute lymphocyte count, neutrophil-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio 2 weeks after treatment initiation for early irAE onset were 820, 4.3, and 2.2, respectively. In multivariable logistic regression analyses, absolute lymphocyte count >820 at 2 weeks after treatment initiation was significantly associated with an increased risk of early onset of any irAE. In contrast, no significant association was observed for the neutrophil-to-lymphocyte ratio (>4.3) or the lymphocyte-to-monocyte ratio (>2.2) at 2 weeks following treatment initiation. Conclusions: The absolute lymphocyte count >820 at 2 weeks following nivolumab initiation predicts early onset of irAEs during a 6-week study period. Routinely available absolute lymphocyte count, which is measured after the initiation of nivolumab, may be useful for identifying patients at risk of early onset of irAEs.

  • Effect of a lever aid on hand strength required for using a handheld inhaler correctly

    Nakada H., Aomori T., Mochizuki M.

    International Journal of Pharmaceutics （International Journal of Pharmaceutics)  596 2021年03月

    研究論文（学術雑誌）, 共著, 査読有り,  ISSN  03785173

    　概要を見る

    © 2021 The Author(s) In the treatment of asthma and chronic obstructive pulmonary disease, using a lever aid to improve drug delivery from an inhaler is recommended for patients with poor muscle strength. However, no studies have investigated the effect on hand strength of using a lever aid. Here, we measured hand strength before and after operating a lever aid and tried to predict the required strength. We compared the pinch force required to activate a pressurized metered dose inhaler (pMDI) and a dry powder inhaler as well as the rotational torque required to activate a soft mist inhaler (SMI) before and after attaching a lever aid. We then assessed the correlation between the theoretical and measured pinch force after fitting the lever aid. Use of the lever aid significantly reduced the pinch force required for pMDI operation from 26.13–48.74 N to 4.90–16.87 N. In contrast, using a lever aid significantly reduced the force needed to rotate SMI, although the rotational torque required to operate did not change. There was a significant positive correlation between the theoretical and measured pinch forces required to activate a pMDI fitted with a lever aid. Using a lever aid will increase the number of patients who can use this device.

  • Peripheral blood biomarkers predict immune-related adverse events in non-small cell lung cancer patients treated with pembrolizumab: A multicenter retrospective study

    Egami S., Kawazoe H., Hashimoto H., Uozumi R., Arami T., Sakiyama N., Ohe Y., Nakada H., Aomori T., Ikemura S., Fukunaga K., Yamaguchi M., Nakamura T.

    Journal of Cancer （Journal of Cancer)  12 （ 7 ） 2105 - 2112 2021年

    研究論文（学術雑誌）, 共著, 査読有り

    　概要を見る

    © 2021 Ivyspring International Publisher. All rights reserved. Background: Pembrolizumab is currently the standard treatment for patients with advanced non-small cell lung cancer (NSCLC). However, the association between immune-related adverse events (irAEs) and peripheral blood cell counts remains unclear. We aimed at identifying peripheral blood cell counts that may predict the development of pembrolizumab-induced irAEs. Methods: We retrospectively analyzed data on consecutive patients with advanced NSCLC who received pembrolizumab monotherapy as first-line or later-line therapy at the National Cancer Center Hospital and Keio University Hospital. We used data between December 2015 and November 2018. The primary endpoint was the relationship between peripheral blood cell count data and early-onset irAEs during the 6-weeks study period. Receiver operating characteristic (ROC) curve and multivariable logistic regression analyses were performed. Results: In total, 92 patients were evaluated, of whom 45 (48.9%) had at least one irAE during the first 6-weeks after treatment initiation. The ROC curves revealed that the optimal cutoff of pretreatment absolute lymphocyte count (ALC), neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), and platelet-to-lymphocyte ratio (PLR) for onset of irAEs were 1459, 2.320, 1.538, and 165, respectively. Multivariable logistic regression analyses revealed that pretreatment ALC>1450 and LMR>1.6 were significantly associated with a reduced risk for onset of any irAEs, whereas pretreatment NLR>2.3 and PLR>165 were significantly associated with an increased risk. Conclusions: The findings suggest that considering the routine availability of blood cell count data before the initiation of treatment with pembrolizumab, it may be useful in identifying early-onset irAEs during the 6-weeks study period in clinical practice.

  • Lorlatinib-induced visual and auditory hallucinations: A case report

    Hakamata J., Nakada H., Muramatsu H., Masuzawa K., Terai H., Ikemura S., Fukunaga K., Aomori T.

    Clinical Case Reports （Clinical Case Reports)  00   1 - 4 2021年

    研究論文（学術雑誌）, 共著, 査読有り

    　概要を見る

    Lorlatinib can cause visual and auditory hallucinations. And, it is necessary to keep in mind that hallucinations can persist even after discontinuation in patients who develop hallucinations while receiving lorlatinib.

全件表示 >>

このページの先頭へ▲

KOARA（リポジトリ）収録論文等 【 表示 ／ 非表示 】

このページの先頭へ▲

総説・解説等 【 表示 ／ 非表示 】

このページの先頭へ▲

研究発表 【 表示 ／ 非表示 】

  • 薬学部と大学病院との連携に関する慶應義塾大学の取り組み

    青森　達

    第31回日本医療薬学会年会, 2021年10月, シンポジウム・ワークショップ パネル（公募）

  • プラセボ効果の個体間変動要因に関する検討.

    間宮桐子, 新井菜々美, 井澤美苗, 石川春樹, 中田英夫, 青森達, 望月眞弓

    第31回日本医療薬学会年会, 2021年10月, ポスター（一般）

  • 改訂コアカリに準拠した実務実習において実習生の パフォーマンスレベルはルーブリック形式の概略評価を用いて測定できる

    河添仁, 鈴木小夜, 平賀ゆい, 横山雄太, 地引綾, 岩田紘樹, 小林典子, 藤本和子, 中田英夫, 青森達, 山浦克典, 中村智徳

    第31回日本医療薬学会年会, 2021年10月, ポスター（一般）

  • 実務実習記録による評価を行う領域におけるCOVID-19 pandemicの影響の検証

    地引綾, 横山雄太, 鈴木小夜, 岩田紘樹, 平賀ゆい, 河添仁, 小林典子, 藤本和子, 中田英夫,青森達, 山浦克典, 中村智徳

    第31回日本医療薬学会年会, 2021年10月, ポスター（一般）

  • COVID-19 pandemic下における薬学実務実習の到達度評価を指標とした学修効果の検証

    鈴木小夜, 平賀ゆい, 岩田紘樹, 地引綾, 横山雄太, 河添仁, 小林典子, 藤本和子, 中田英夫,青森達, 山浦克典, 中村智徳

    第31回日本医療薬学会年会, 2021年10月, ポスター（一般）

全件表示 >>

このページの先頭へ▲

競争的資金等の研究課題 【 表示 ／ 非表示 】

  • AI を用いた医薬品の未承認・禁忌・適応外使用データベースの構築と医療安全への応用

    2019年

    2019年度慶應義塾学事振興資金（個人研究）, 青森達, 青森達, 補助金,  代表

  • 慢性呼吸器疾患治療の高度化と標準化に向けた吸入動作評価技術の開発研究

    2019年

    日本医療研究開発機構研究費, 橋渡し研究戦略的推進プログラム, 下野誠通, 補助金,  分担

  • 生活者にとって分かりやすい要指導・一般用医薬品添付文書の構成に関する研究

    2018年
    -
    2020年

    日本医療研究開発機構研究費, 望月眞弓, 受託研究,  分担

  • プラセボ効果の個体間変動要因：プラセボームとパーソナリティ解析による個別薬物療法

    2018年
    -
    2020年

    日本学術振興会科学研究費補助金, 基盤研究 (C), 井澤美苗, 補助金,  分担

  • ゲノム医療従事者の育成プログラム開発

    2018年
    -
    2020年

    日本医療研究開発機構研究費, 豊岡伸一, 受託研究,  分担

全件表示 >>

このページの先頭へ▲

受賞 【 表示 ／ 非表示 】

  • 優秀演題賞

    富永佳子, 青森達, 早川智久, 井澤美苗, 望月眞弓, 2018年10月, 第7回日本くすりと糖尿病学会学術集会, 糖尿病患者の服薬アドヒアランス不良リスク推定モデルの作成と介入支援ツールの構築 －患者への個別化対応実践のために－.

    受賞区分： 国内学会・会議・シンポジウム等の賞

  • 学生優秀発表賞

    富永佳子, 青森達, 早川智久, 望月眞弓, 2018年03月, 日本薬学会第138年会,, 糖尿病患者におけるアドヒアランス影響因子に関する研究－内的要因としての病識に着目した探索的検討－

    受賞区分： 国内学会・会議・シンポジウム等の賞

  • 優秀発表賞

    菊山史博, 鈴木小夜, 高木彰紀, 地引綾, 横山雄太, 青森達, 中村智徳, 2017年09月, 第2回日本薬学教育学会大会, 薬学実務実習が実習生の専門知識（C1～C18）の定着及び新規構築に与える影響

    受賞区分： 国内学会・会議・シンポジウム等の賞

  • 優秀ポスター発表賞

    羽田有里, 青森達, 坡下真大, 荒木拓也, 山本康次郎, 鈴木小夜, 地引綾, 中村智徳, 2015年09月, 第59回日本薬学会関東支部大会, アプレピタントによる補助療法ががん化学療法の治療経過に与える影響

    受賞区分： 国内学会・会議・シンポジウム等の賞

  • 第66回日本食道学会学術集会優秀ポスター演題賞(メディカルスタッフ)

    荒木聖美、長嶺 歩、青森 達、荒木拓也、飯塚恵子、田中成岳、浅尾高行、桑野博行、中村智徳、山本康次郎., 2012年06月, 日本食道学会, 食道癌化学放射線療法における免疫栄養剤併用の有用性.

    　説明を見る

    　

全件表示 >>

このページの先頭へ▲
 

担当授業科目 【 表示 ／ 非表示 】

  • 実務実習事前学習３

    2021年度

  • 実務実習の前に（６）

    2021年度

  • 実務実習の前に（５）

    2021年度

  • 実務実習の前に（４）

    2021年度

  • 実務実習の前に（３）

    2021年度

全件表示 >>

このページの先頭へ▲